Skip to main content
Erschienen in: Pituitary 1/2013

01.03.2013

Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion

verfasst von: Teresa Gagliano, Carlo Filieri, Mariella Minoia, Mattia Buratto, Federico Tagliati, Maria Rosaria Ambrosio, Marcello Lapparelli, Matteo Zoli, Giorgio Frank, Ettore degli Uberti, Maria Chiara Zatelli

Erschienen in: Pituitary | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Dopamine (DA) therapy of non-functioning pituitary adenomas (NFA) can result in tumor stabilization and shrinkage. However, the mechanism of action is still unknown. Previous evidence showed that DA can inhibit pituitary vascular endothelial growth factor expression (VEGF), that may be involved in pituitary tumor growth. The aim of our study was to clarify whether VEGF secretion modulation might mediate the effects of DA agonists on cell proliferation in human NFA. We assessed DA receptor subtype 2 (DR2) expression in 20 NFA primary cultures, where we also investigated the effects of a selective DR2 agonist, cabergoline (Cab), on VEGF secretion and on cell viability. All NFA samples expressed α-subunit and DR2 was expressed in 11 samples. In DR2 expressing tumors, Cab significantly reduced cell viability (−25%; P < 0.05) and VEGF secretion (−20%; P < 0.05). These effects were counteracted by treatment with the DA antagonist sulpiride. Cab antiproliferative effects were blocked by VEGF. Our data demonstrate that Cab, via DR2, inhibits cell viability also by reducing VEGF secretion in a selected group of NFA, supporting that DA agonists can be useful in the medical therapy of DR2 expressing NFA.
Literatur
1.
Zurück zum Zitat Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724–763PubMedCrossRef Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724–763PubMedCrossRef
2.
Zurück zum Zitat Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189–225PubMed Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189–225PubMed
3.
Zurück zum Zitat Adams EF, Ashby MJ, Brown SM, White MC, Mashiter K (1981) Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism. Clin Endocrinol (Oxf) 15:479–484CrossRef Adams EF, Ashby MJ, Brown SM, White MC, Mashiter K (1981) Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism. Clin Endocrinol (Oxf) 15:479–484CrossRef
4.
Zurück zum Zitat Yin D, Kondo S, Takeuchi J, Morimura T (1994) Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett 339:73–75PubMedCrossRef Yin D, Kondo S, Takeuchi J, Morimura T (1994) Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett 339:73–75PubMedCrossRef
5.
Zurück zum Zitat Bevan JS, Burke CW (1986) Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol 25:561–572CrossRef Bevan JS, Burke CW (1986) Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol 25:561–572CrossRef
6.
Zurück zum Zitat Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A, Lange M, Weindl A, Stalla GK (1998) Heterogenous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 83:1368–1375PubMedCrossRef Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A, Lange M, Weindl A, Stalla GK (1998) Heterogenous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 83:1368–1375PubMedCrossRef
7.
Zurück zum Zitat Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L, Lombardi G (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89:1674–1683PubMedCrossRef Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L, Lombardi G (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89:1674–1683PubMedCrossRef
8.
Zurück zum Zitat Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G (1998) Correlation of scintigraphic results using 123I-Methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 83:248–252PubMedCrossRef Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G (1998) Correlation of scintigraphic results using 123I-Methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 83:248–252PubMedCrossRef
9.
Zurück zum Zitat Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S (2008) Medical treatment for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15:905–915PubMedCrossRef Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S (2008) Medical treatment for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15:905–915PubMedCrossRef
10.
Zurück zum Zitat Chanson P, Brochier S (2005) Non-functioning pituitary adenomas. J Endocrinol Invest 28:93–99PubMed Chanson P, Brochier S (2005) Non-functioning pituitary adenomas. J Endocrinol Invest 28:93–99PubMed
11.
Zurück zum Zitat Greenman Y, Tordjman K, Osher E, Veshchev I, Shenkerman G, Reider-Groswasser II, Segev Y, Ouaknine G, Stern N (2005) Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumor remnant growth. Clin Endocrinol (Oxf) 63:39–44CrossRef Greenman Y, Tordjman K, Osher E, Veshchev I, Shenkerman G, Reider-Groswasser II, Segev Y, Ouaknine G, Stern N (2005) Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumor remnant growth. Clin Endocrinol (Oxf) 63:39–44CrossRef
12.
Zurück zum Zitat Greenman Y, Stern N (2009) Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23:625–638PubMedCrossRef Greenman Y, Stern N (2009) Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23:625–638PubMedCrossRef
13.
Zurück zum Zitat Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14:91–102PubMedCrossRef Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14:91–102PubMedCrossRef
14.
Zurück zum Zitat Ochoa AL, Mitchner NA, Paynter CD, Morris RE, Ben-Jonathan N (2000) Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. J Endocrinol 165:483–492PubMedCrossRef Ochoa AL, Mitchner NA, Paynter CD, Morris RE, Ben-Jonathan N (2000) Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. J Endocrinol 165:483–492PubMedCrossRef
15.
Zurück zum Zitat Vidal S, Lloyd RV, Moya L, Scheithauer BW, Kovacs K (2002) Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary. J Histochem Cytochem 50:533–540PubMedCrossRef Vidal S, Lloyd RV, Moya L, Scheithauer BW, Kovacs K (2002) Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary. J Histochem Cytochem 50:533–540PubMedCrossRef
16.
Zurück zum Zitat Banerjee SK, Zoubine MN, Tran TM, Weston AP, Campbell DR (2000) Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells. Int J Oncol 16:253–260PubMed Banerjee SK, Zoubine MN, Tran TM, Weston AP, Campbell DR (2000) Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells. Int J Oncol 16:253–260PubMed
17.
Zurück zum Zitat Kim K, Yoshida D, Teramoto A (2005) Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol 16:115–121PubMedCrossRef Kim K, Yoshida D, Teramoto A (2005) Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol 16:115–121PubMedCrossRef
18.
Zurück zum Zitat Onofri C, Carbia Nagashima A, Schaaf L, Feirer M, Lohrer P, Stummer W, Berner S, Chervin A, Goldberg V, Stalla GK (2004) Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas. Exp Clin Endocrinol Diabetes 112:18–23PubMedCrossRef Onofri C, Carbia Nagashima A, Schaaf L, Feirer M, Lohrer P, Stummer W, Berner S, Chervin A, Goldberg V, Stalla GK (2004) Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas. Exp Clin Endocrinol Diabetes 112:18–23PubMedCrossRef
19.
Zurück zum Zitat Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L (1999) Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229–235PubMedCrossRef Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L (1999) Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229–235PubMedCrossRef
20.
Zurück zum Zitat McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJL (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–4244PubMedCrossRef McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJL (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–4244PubMedCrossRef
21.
Zurück zum Zitat Cristina C, Dıaz-Torga G, Baldi A, Gongola A, Rubinstein M, Low MJ, Becu-Villalobos D (2005) Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology 146:2952–2962PubMedCrossRef Cristina C, Dıaz-Torga G, Baldi A, Gongola A, Rubinstein M, Low MJ, Becu-Villalobos D (2005) Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology 146:2952–2962PubMedCrossRef
22.
Zurück zum Zitat Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD, degli Uberti EC (2003) Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. J Clin Endocrinol Metab 88:2797–2802PubMedCrossRef Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD, degli Uberti EC (2003) Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. J Clin Endocrinol Metab 88:2797–2802PubMedCrossRef
23.
Zurück zum Zitat Danila D, Sleiman Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A (2001) Somatostatin receptor specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 86:2976–2981PubMedCrossRef Danila D, Sleiman Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A (2001) Somatostatin receptor specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 86:2976–2981PubMedCrossRef
24.
Zurück zum Zitat Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC (2004) Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 89:5181–5188PubMedCrossRef Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC (2004) Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 89:5181–5188PubMedCrossRef
25.
Zurück zum Zitat Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VE, Post KD, Vance ML (2011) Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:894–904PubMedCrossRef Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VE, Post KD, Vance ML (2011) Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:894–904PubMedCrossRef
26.
Zurück zum Zitat Turner HE, Stratton IM, Byrne JV, Adams CB, Wass JA (1999) Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation—a follow-up study. Clin Endocrinol (Oxf) 51:281–284CrossRef Turner HE, Stratton IM, Byrne JV, Adams CB, Wass JA (1999) Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation—a follow-up study. Clin Endocrinol (Oxf) 51:281–284CrossRef
27.
Zurück zum Zitat Park P (2004) The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55:100–106PubMedCrossRef Park P (2004) The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55:100–106PubMedCrossRef
28.
Zurück zum Zitat Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumor quiescence and regrowth. Clin Endocrinol (Oxf) 58:763–769CrossRef Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumor quiescence and regrowth. Clin Endocrinol (Oxf) 58:763–769CrossRef
29.
Zurück zum Zitat Reddy R, Cudlip S, Byrne JV, Karavitaki N, Wass JA (2011) Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur J Endocrinol 165:739–744PubMedCrossRef Reddy R, Cudlip S, Byrne JV, Karavitaki N, Wass JA (2011) Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur J Endocrinol 165:739–744PubMedCrossRef
30.
Zurück zum Zitat Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JA (2007) What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 67:938–943CrossRef Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JA (2007) What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 67:938–943CrossRef
31.
Zurück zum Zitat Greenman Y (2007) Dopaminergic treatment of nonfunctioning pituitary adenomas. Nat Clin Pract Endocrinol Metab 3:95–101CrossRef Greenman Y (2007) Dopaminergic treatment of nonfunctioning pituitary adenomas. Nat Clin Pract Endocrinol Metab 3:95–101CrossRef
32.
Zurück zum Zitat Florio T, Barbieri F, Spaziante R (2008) Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 15:583–596PubMedCrossRef Florio T, Barbieri F, Spaziante R (2008) Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 15:583–596PubMedCrossRef
33.
Zurück zum Zitat Peverelli E, Olgiati L, Locatelli M, Magni P, Fustini MF, Frank G, Mantovani G, Beck-Peccoz P, Spada A, Lania A (2010) The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett 28(288):170–176CrossRef Peverelli E, Olgiati L, Locatelli M, Magni P, Fustini MF, Frank G, Mantovani G, Beck-Peccoz P, Spada A, Lania A (2010) The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett 28(288):170–176CrossRef
34.
Zurück zum Zitat Niveiro M, Aranda FI, Peiró G, Alenda C, Picó A (2005) Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol 36:1090–1095PubMedCrossRef Niveiro M, Aranda FI, Peiró G, Alenda C, Picó A (2005) Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol 36:1090–1095PubMedCrossRef
35.
Zurück zum Zitat Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK, Renner U (2006) Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol 191:249–261PubMedCrossRef Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK, Renner U (2006) Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol 191:249–261PubMedCrossRef
36.
Zurück zum Zitat Korsisaari N, Ross J, Wu X, Kowanetz M, Pal N, Hall L, Eastham-Anderson J, Forrest WF, Van Bruggen N, Peale FV, Ferrara N (2008) Blocking vascular endothelial growth factor-a inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res 14:249–258PubMedCrossRef Korsisaari N, Ross J, Wu X, Kowanetz M, Pal N, Hall L, Eastham-Anderson J, Forrest WF, Van Bruggen N, Peale FV, Ferrara N (2008) Blocking vascular endothelial growth factor-a inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res 14:249–258PubMedCrossRef
37.
Zurück zum Zitat Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D (2001) The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569–570PubMedCrossRef Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D (2001) The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569–570PubMedCrossRef
38.
Zurück zum Zitat Luque GM, Perez-Millán MI, Ornstein AM, Cristina C, Becu-Villalobos D (2011) Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. J Pharmacol Exp Ther 337:766–774PubMedCrossRef Luque GM, Perez-Millán MI, Ornstein AM, Cristina C, Becu-Villalobos D (2011) Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. J Pharmacol Exp Ther 337:766–774PubMedCrossRef
39.
Zurück zum Zitat Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K (2011) Anti-VEGF therapy in pituitary carcinoma. Pituitary. Sep 15. [Epub ahead of print] Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K (2011) Anti-VEGF therapy in pituitary carcinoma. Pituitary. Sep 15. [Epub ahead of print]
Metadaten
Titel
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion
verfasst von
Teresa Gagliano
Carlo Filieri
Mariella Minoia
Mattia Buratto
Federico Tagliati
Maria Rosaria Ambrosio
Marcello Lapparelli
Matteo Zoli
Giorgio Frank
Ettore degli Uberti
Maria Chiara Zatelli
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 1/2013
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-012-0380-1

Weitere Artikel der Ausgabe 1/2013

Pituitary 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.